Study: Expanded CER Process Will Reduce Investment in Medical Technologies by $10 B | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Study: Expanded CER Process Will Reduce Investment in Medical Technologies by $10 B

July 14, 2011
by root
| Reprints

A new research study released by the Pacific Research Institute (PRI), a San Francisco-based free-market think tank, examines an expanded quasi-federal comparative effectiveness review (CER) process and the negative effects on private-sector investment in research and development of new and improved medical technologies. Under conservative assumptions, R&D investment in pharmaceuticals, medical devices and equipment would be reduced by about $10 billion per year over the period from 2014 through 2025. "Medicare Auctions for Durable Medical Equipment" was authored by PRI senior policy fellow Benjamin Zycher, Ph.D.

Comparative Effectiveness Review (CER) is defined by the Congressional Budget Office as "a rigorous evaluation of the impact of different options that are available for treating a given medical condition for a particular set of patients." Because policymakers have powerful incentives to restrain the growth of health care expenditures, an expanded federal role in CER, whether direct or indirect, will induce responses from the private sector as a result of expectations of how CER findings will be used by policymakers. For firms investing in and developing medical technologies, these expectations include an increased need for private clinical testing, increased pricing pressures, increased risk of non-approval or limited approval for federally-financed programs, a shortening of the patent period and delays in expected sales revenues.

Using data from the National Science Foundation and other sources, the report concludes that under conservative assumptions, R&D investment in new and improved pharmaceuticals and medical devices and equipment would be reduced by about 10-12 percent. This reduction in the flow of new and improved technology would impose an expected loss of about 5 million life-years annually, with a conservative economic value of $500 billion - an amount substantially greater than the entire U.S. market for pharmaceuticals, devices and equipment.


Topics

News

House Committee Presses Nuance Executives on NotPetya Attack

he U.S. House Energy and Commerce Committee is requesting that Nuance Communications executives provide more information about the malware incident, called NotPetya, that impacted the company, along with multinational companies in 65 countries, back in June.

Regenstrief Researchers to Study Impact of HIE on Emergency Care

Scientists at the Indianapolis-based Regenstrief Institute are conducting what they say is the first study of health information exchange (HIE) use over multiple years to evaluate whether it improves patient outcomes in emergency departments.

Report: Healthcare Organizations Struggle with Human Error in Securing PHI

In the first nine months of 2017, unintended disclosure accounted for 41 percent of healthcare data breach incidents, according to a report from specialist insurer Beazley.

Three More Providers Receive 2017 HIMSS Davies Awards

Three patient care organizations have received the 2017 global Healthcare Information and Management Systems Society (HIMSS) Enterprise Nicholas E. Davies Award of Excellence for healthcare technology innovations that improve patient outcomes.

Medtronic, American Well Team Up to Integrate Telehealth Capabilities

Medtronic and American Well announced a partnership to offer a telehealth solution focused on the unique needs of the complex, chronic, co-morbid patient population.

Medsphere Merges with RCM Vendor Stockell

Medsphere Systems Corp., developer of the OpenVista electronic health record, is merging with Stockell Healthcare Systems, which offers a suite of revenue cycle management tools.